NRX Pharmaceuticals, Inc. (NRXP)

Nurix Therapeutics (NRIX) Q1 2026 earnings: EPS $-0.79 vs $-0.76 est. (MISS by 3.3%). Revenue $6.3M vs $14.2M est. View earnings history, market reaction charts, and AI analysis.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for NRx Pharmaceuticals in a note issued to investors on Monday, April 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

Get real-time NRX Pharmaceuticals Inc (NRXP) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?